5 Top Gainers In Healthcare Sector (TRXC, OHRP, VNRX...)

pharmaup july10

The following are some of today's top gainers in the pharma/biotech sector.

1. Valeritas Holdings Inc. (VLRX)

The Company is a maker of V-Go wearable insulin delivery device. V-Go won 510(k) clearance from the FDA in 2010 and CE Mark approval in the European Union in 2011.

Gained 27.55% to close Wednesday's (July 10) trading at $3.75.

News: No news

Recent event:

On June 27, 2019, the Company filed a "Special 510(k): Device Modification" submission with the FDA that includes using regular human insulin in the device. If cleared, this would allow for a labeling change that would result in using an insulin that could be substantially less expensive for patients.

Currently, V-Go is cleared for use with a U100 fast-acting insulin such as rapid-acting insulin (RAI) analogs. The list price for analogs is significantly higher than regular human insulin.


For the second quarter of 2019, the Company expects revenue of $7.4 million to $7.6 million, and for the full year 2019, revenue is expected to be between $31.0 million and $34.0 million.

2. TransEnterix Inc. (TRXC)

The Company's flagship product is Senhance Surgical Robotic System. The device received FDA clearance for colorectal and gynecological laparoscopic surgery in October 2017, becoming the first new entrant to abdominal robotics in the U.S. since 2000.

Gained 25.98% to close Wednesday's trading at $1.60.

News: The Company announced the sale of certain AutoLap image-based laparoscope positioning system assets to Great Belief International Limited (GBIL) for $17 million. In addition, GBIL is making an equity investment of $30.0 million in TransEnterix common stock at $2.00 per share, payable on or before September 30, 2019.

3. Trinity Biotech plc (TRIB)

Trinity Biotech is a developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets.

Gained 15.79% to close Wednesday's trading at $2.20.

News: No news

Recent event:

On March 7, 2019, the Company announced financial results for the quarter ended December 31, 2018 and fiscal year 2018. Total revenues for fiscal year 2018 were $97.0 million compared to $99.1 million in 2017, a decrease of 2% year on year.

4. OHR Pharmaceutical Inc. (OHRP)

Gained 15.18% to close Wednesday's trading at $4.25.

News: The Company's stockholders have approved of its proposed merger with NeuBase Therapeutics Inc.

Upon closing of the transaction, the combined company will change its name to "NeuBase Therapeutics Inc.", and the NASDAQ trading symbol will become "NBSE".

The executive team of NeuBase will serve as the executive team of the combined company, led by Dietrich A. Stephan, Ph.D. as Chief Executive Officer.

5. VolitionRx Limited (VNRX)

VolitionRx is focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers.

Gained 13.13% to close Wednesday's trading at $3.36.

News: The Company has been awarded additional non-dilutive funding in the form of a non-repayable cash grant totaling approximately $1.4 million from the Walloon Region, Belgium. This grant will support a specific project to be conducted in collaboration with GIGA at the University of Liege, Belgium.

GIGA is the University of Liège's interdisciplinary research institute in the biomedical sciences.

For comments and feedback contact: editorial@rttnews.com

Follow RTT